BCL2A1 as A Potential Drug Target and Biomarker (G597)

Target Name: BCL2A1

NCBI ID: G597

BCL2A1

BCL2A1 as A Potential Drug Target and Biomarker

BCL2A1 (BFL1), a gene that encodes a protein known as BCL2-associated protein 1, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions and interactions with other proteins in the BCL2 signaling pathway have been extensively studied, providing insights into its potential clinical applications.

The BCL2 signaling pathway is a critical regulator of cell growth, apoptosis, and inflammation. It consists of the BCL2 protein, which serves as a negative regulator of the BCL2-associated protein 2 (BAP2) complex, and several downstream targets, including Bax, p53, and co-expression of BAP2 and BCL2. BCL2 is involved in the regulation of cell cycle progression, apoptosis, and DNA repair, and has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The BCL2-associated protein 1 (BAP1) is a protein that is highly co-expressed with BCL2 in various tissues and cells. It has been shown to interact with BCL2 and to play a role in the regulation of BCL2-associated protein 2 (BAP2 ) stability and activity. BAP1 has also been shown to interact with other proteins, including PDGF-尾, TGF-β, and NF-kappa-B.

In cancer, BCL2 and BAP1 have been implicated in the regulation of cell cycle progression, apoptosis, and angiogenesis. BCL2 has been shown to inhibit the G1 checkpoint, which is a critical regulatory checkpoint that ensures the stay in G1 phase of the cell cycle in response to growth factors. This inhibition allows cells to bypass the G1 checkpoint and continue to divide uncontrollably, leading to the formation of cancer cells. BAP1 has been shown to regulate BCL2-associated protein 2 (BAP2) stability and activity, which is a critical protein for the regulation of BCL2-associated protein 2 (BAP2) stability and activity. BAP2 is a key regulator of the BCL2-associated protein 2 (BAP2) complex, which is involved in the regulation of cell cycle progression, apoptosis, and DNA repair.

In neurodegenerative diseases, BCL2 and BAP1 have been implicated in the regulation of neurodegeneration. BCL2 has been shown to regulate the neurotransmitter synthesis and release, as well as the modulation of ion channels, which are critical for neurotransmitter signaling. BAP1 has been shown to interact with BCL2 and to play a role in the regulation of BCL2-associated protein 2 (BAP2) stability and activity. BAP2 is a key regulator of the BCL2-associated protein 2 (BAP2) complex, which is involved in the regulation of cell cycle progression , apoptosis, and DNA repair.

In autoimmune disorders, BCL2 and BAP1 have been implicated in the regulation of immune cell function. BCL2 has been shown to regulate the activation and proliferation of immune cells, as well as the regulation of inflammation. BCL2 has been shown to interact with BCL2 and to play a role in the regulation of BCL2-associated protein 2 (BAP2) stability and activity. BAP2 is a key regulator of the BCL2-associated protein 2 (BAP2) complex, which is involved in the regulation of cell cycle progression, apoptosis, and DNA repair.

In conclusion, BCL2A1 (BFL1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions and interactions with other proteins in the BCL2 signaling pathway have been extensive studied, providing insights into its potential clinical applications. Further research is needed to fully understand the role of BCL2A1 (BFL1) in the regulation of

Protein Name: BCL2 Related Protein A1

Functions: Retards apoptosis induced by IL-3 deprivation. May function in the response of hemopoietic cells to external signals and in maintaining endothelial survival during infection (By similarity). Can inhibit apoptosis induced by serum starvation in the mammary epithelial cell line HC11 (By similarity)

The "BCL2A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BCL2A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets